# An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis

> **NCT04520308** · PHASE4 · UNKNOWN · sponsor: **Eric Simpson** · enrollment: 45 (estimated)

## Conditions studied

- Atopic Dermatitis
- AD
- Eczema

## Interventions

- **DRUG:** Dupilumab Only Product

## Key facts

- **NCT ID:** NCT04520308
- **Lead sponsor:** Eric Simpson
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2021-02-26
- **Final completion:** 2021-03-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2020-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04520308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04520308, "An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04520308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*